Israeli Biomed Stocks: Not What the Broker Ordered

While U.S. shares just finished a nice five-year run, their Israeli counterparts lost 60%. The reason: No profits.

comments Print
When the American biotechnology company MannKind registered to trade on the Tel Aviv Stock Exchange in October, more than a few investors were worried.